CTLT240517P55000
- 0.10
- 0.000.00%
Catalent Newsroom
Express News | Novo Nordisk CEO Says "Over The Next Quarter Seeing A Steady Flow Of Trial Data For Semaglutide"; "When We Now Launch In New Countries, We Want To Do It In A Way Where We Set Aside A Defined Capacity" For Obesity Drug; "Pleased With" The Catalent...
Express News | Novo Nordisk CEO Says "There Are a Lot of Contract Manufacturers Knocking Our Door Almost on a Weekly Basis"
Express News | Novo Nordisk CEO Says in Addition to Catalent Sites, Co Will Continue Working With Contract Manufacturers
Express News | Novo Nordisk CEO Says Catalent Deal Will Bring Three Large Sites to Co, and There's Ample Expansion Opportunity on Those Sites
Express News | Novo Nordisk CEO Says "Pleased With" the Catalent Acquisition That We're Now Working on and We Expect to Close in This Year
Express News | NYSE Order Imbalance 119777.0 Shares on Buy Side
Argus Downgrades Catalent to Sell From Buy
Catalent (CTLT) has an average hold rating and a price target range of $46 to $63.50, according to analysts polled by Capital IQ. Price: 55.42, Change: -0.19, Percent Change: -0.34
Unusual Options Activity: GameStop, PBR, and Others Attract Market Bets
EST May 15th Afternoon Delivery - In the last two hours of trading, 5 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends
Express News | NYSE Order Imbalance 198826.0 Shares on Buy Side
Update: Market Chatter: Novo Nordisk Taps Banks for Potential Bond Issue
(Updates to add Novo Nordisk's response) Novo Nordisk (NOVO-B.CO) hired banks for the potential issue of euro-nominated bonds to fund general corporate purposes, including funding its $16.5 billion ac
Form 144 | Catalent(CTLT.US) Insider Proposes to Sell 176.62K in Common Stocks
SEC FILLINGS DISCLOSED/ May 13, $Catalent(CTLT.US)$ Insider Crane Rosemary A intends to sell 3,167 shares of its common stock on May 13, with a total market value of approximately $176.62K. Crane Ro
Express News | NYSE Order Imbalance 68977.0 Shares on Buy Side
Market Chatter: Novo Nordisk Taps Banks for Potential Bond Issue
Novo Nordisk (NOVO-B.CO) hired banks for the potential issue of euro-nominated bonds to fund general corporate purposes, including funding its $16.5 billion acquisition of US-based Catalent. Bloomberg
Catalent's (CTLT) Latest Partnership to Boost Clinical Trials
Catalent's Merger Deal With Novo Holdings: A Tightrope Walk Amidst Restrictive Clauses and Hefty Termination Fees
Catalent's Resilient Growth and Positive Outlook Reinforce Buy Rating
Catalent (CTLT) Q3 Earnings Lag Estimates, Gross Margin Up
Catalent, Inc. CTLT reported third-quarter fiscal 2024 adjusted loss per share of 6 cents, which was narrower than the year-ago period’s loss per share of 9 cents.
RBC Capital Sticks to Their Hold Rating for Catalent (CTLT)
Decoding Catalent Inc (CTLT): A Strategic SWOT Insight
On May 8, 2024, Catalent Inc (NYSE:CTLT), a leading contract development and manufacturing organization (CDMO), filed its 10-Q report, offering a glimpse into its financial health and operational performance.
Catalent (CTLT) Reports Q3 Loss, Misses Revenue Estimates
Catalent (CTLT) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of $0.24.